Ladenburg lowered the firm’s price target on Eledon Pharmaceuticals (ELDN) to $20.50 from $28 and keeps a Buy rating on the shares. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback